Web Exclusives

Data security in pharma marketing—the path to maturity

Data security in pharma marketing—the path to maturity

What brand managers need to know to achieve data security maturity

Blockbuster Drug Boycott? What ESI's Sovaldi Threat Means to Big Pharma

Blockbuster Drug Boycott? What ESI's Sovaldi Threat Means to Big Pharma

Express Scripts warned of building an anti-Sovaldi coalition. If payers are unwilling to pay for such drugs, or band against their makers, where does pharma go from here?

Marketing in the Modern Attention Economy: 9 "M-Words" Modern CMOs Should Consider

Marketing in the Modern Attention Economy: 9 "M-Words" Modern CMOs Should Consider

Nine things CMOs should consider when desiring to engage consumers who no longer want to give their attention to boring and scripted product descriptions.

Gens X, Y and diabetes: Not as invincible as they think?

Gens X, Y and diabetes: Not as invincible as they think?

Are today's young adults on their way to healthier lives in middle age and beyond? New data from GfK's Roper Diabetes study series gives cause for concern.

A Message About Messages

A Message About Messages

More credit ought to be given to the investments and inventions made by the biopharmaceutical sector—no question. But placing responsibility on the media for a perceived lack of fairness seems misplaced.

Surging Enrollment—Has the Affordable Care Act Turned a Corner?

Surging Enrollment—Has the Affordable Care Act Turned a Corner?

With enrollment having just reached five million in a push to the March 31 deadline, the ACA is poised to turn the corner of public opinion.

SXSW: Key takeaways for healthcare marketers

SXSW: Key takeaways for healthcare marketers

Why I left SXSW this past week feeling like I just might live forever

How social business is transforming healthcare

How social business is transforming healthcare

Healthcare companies are partnering with social entrepreneurs to drive their own agendas on affordability and access while staying at the forefront of global initiatives

Five things big pharma can learn from the rare-disease community

Five things big pharma can learn from the rare-disease community

Incentives aren't the only reason orphan drugs are a success. More important are the lessons companies have learned about patients, social media and support.

Unraveling the real story in the data trail: people

Unraveling the real story in the data trail: people

Being decoded helps harness technology to bring out the best in people, attract talent and, ultimately, improve customer service, say authors of a new book

Email Newsletters